Table 1.

IC₅₀s (μM) against human prostate cancers after 24, 48, and 72 h exposure to haloenol inhibitors^a

compd	LNCaP			PC-3
	24	48	72	24	48	72
rac-BEL	13	5	9	34	26	14
2a	10	5	5	19	23	14
2b	9	5	7	32	15	16
rac-4	31	5	4	27	10	6
(S)-14a	8	3	3	15	13	5
(R)-14b	6	6	3	8	6	3
(S)-15	26	23	20	21	21	25
(S)-16	41	26	32	33	57	39
17	25	29	28	13	10	7
(S)-20	3	4	3	4	1	4

^aData represent the calculated IC₅₀ using data assessed 3–5 experiments ran in duplicate using separate passages of cells assessing alteration in MTT staining.